Oncology & Hematology Coding Alert

Reader Questions:

Neoplasm Dx Goes First With Estrogen Status

Question: Can you explain how to report estrogen receptor status? Must you report a breast neoplasm diagnosis as primary or secondary with V86.x? Connecticut Subscriber Answer: Yes, you should report a breast neoplasm code (either 174.x, Malignant neoplasm of female breast; or 175.x, Malignant neoplasm of male breast, as appropriate) as the first-sequenced diagnosis with V86.x (Estrogen receptor status). When you look up V86.x in the ICD-9 manual, you are instructed to "Code first malignant neoplasm of breast (174.0-174.9, 175.0-175.9)." Example: For a female patient with a malignant breast neoplasm and estrogen receptor positive status, you should report the neoplasm (174.x) and then the estrogen receptor status with V86.0 (Estrogen receptor positive status [ER+]). For negative status, you would report 174.x for the neoplasm and then V86.1 (Estrogen receptor negative status [ER-]). Go to the source: For complete information on reporting V86.x, you can view the official guidelines in Section 1.C.18.d.3. of the ICD-9 manual or online at http://www.cdc.gov/nchs/datawh/ftpserv/ftpicd9/icdguide08.pdf. -- Technical and coding advice for You Be the Coder and Reader Questions provided by Cindy C. Parman, CPC, CPC-H, RCC, co-owner of Coding Strategies Inc. in Powder Springs, Ga., and past president of the American Academy of Professional Coders National Advisory Board.
Codify by AAPC
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All
Subscribe to newsletter